Cerchietti Research Lab

Publications

Found 23 results

Filters: First Letter Of Last Name is I [Clear All Filters]

2013

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al.. 2013. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

2014

Patel RGhanshyam, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, Singh A. 2014. Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications.. Cell Mol Bioeng. 7(3):394-408.

Irmady K, Jackman KA, Padow VA, Shahani N, Martin LAndres, Cerchietti L, Unsicker K, Iadecola C, Hempstead BL. 2014. Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury.. J Neurosci. 34(9):3419-28.

Irmady K, Jackman KA, Padow VA, Shahani N, Martin LAndres, Cerchietti L, Unsicker K, Iadecola C, Hempstead BL. 2014. Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury.. J Neurosci. 34(9):3419-28.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ. 2014. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ. 2014. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.

2015

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al.. 2015. Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al.. 2015. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al.. 2015. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

2016

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al.. 2016. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al.. 2016. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

2017

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al.. 2017. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.

2020

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al.. 2020. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al.. 2020. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Fiore D, Cappelli LVincenzo, Zumbo P, Phillips JM, Liu Z, Cheng S, Yoffe L, Ghione P, Di Maggio F, Dogan A et al.. 2020. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries.. Cancers (Basel). 12(6)

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al.. 2020. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

2021

Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciapuoti MTeresa, Mensah AAdjeiwaa, Sartori G, Munz N et al.. 2021. Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.. Haematologica.

Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MTeresa, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N et al.. 2021. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures.. Cancer Discov.

M Calvo-Vidal N, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J et al.. 2021. Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.. Cancer Res. 81(20):5202-5216.

2023

Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al.. 2023. Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.

Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al.. 2023. Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.

2024

Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al.. 2024. Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.

Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J et al.. 2024. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. Cancer Res. 84(1):101-117.